The rebellion , which took place at the company 's annual general meeting on 18 march , saw shareholders reject bonuses at the pharmaceutical firm due to concerns about disclosure and outcomes related to the company ’s incentive scheme . The interim report , which is non - binding , was rejected by the remaining 65 % of shareholders . Although the pay of CEO Pascal Soriot ranged from a previous £ 14.3 m ( $ 19.2 m ) to £ 9.4 m in 2017 , advisory group Institutional Shareholder Services still recommended rejecting the report , stating that a series of high bonuses suggested the bar had been paid too low by the firm .
The rebellion, which took place at the company's annual general meeting on 18 May, saw shareholders reject bonuses at the pharmaceutical firm due to concerns about disclosure and outcomes related to the company’s incentive scheme. The pay report, which is non-binding, was endorsed by the remaining 65% of shareholders. Although the pay of CEO Pascal Soriot fell from a previous £14.3m ($19.2m) to £9.4m in 2017, advisory group Institutional Shareholder Services still recommended rejecting the report, arguing that a series of high bonuses suggested the bar had been set too low by the firm.